| A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease |
Ongoing |
Osivelotor |
2/3 |
C5351004 (GBT021601) |
Prince Mohammad Bin Naser Hospital (Jazan), King Abdulaziz Medical City NG (Riyadh) |
| Effect and safety of Semaglutide in diabetic kidney transplant recipients with obesity |
Ongoing |
Anifrolumab |
3 |
2241130 |
Aseer Central Hospital (Abha), International Medical Center (Jeddah), King Khalid University Hospital (Riyadh) |
| Comparing the effectiveness of buccal infiltration of different volumes of Articaine for extraction of mandibular posterior teeth- A randomized clinical trial. |
Ongoing |
ARTICAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE |
4 |
6074514624 |
Dental Clinic-collage of Dentistry-Qassim Unviersity (Al-Qassim) |
| The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency |
Ongoing |
INZ-701 |
3 |
INZ701-105 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| INTERnational STudy Evaluating Lupus Outcomes after Anifrolumab Real-World Use (INTERSTELLAR): Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice |
Ongoing |
Anifrolumab |
4 |
TMP-0010230 |
Aseer Central Hospital (Abha), International Medical Center (Jeddah) |
| A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment |
Ongoing |
amlitelimab |
3 |
EFC17599 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease |
Ongoing |
Camizestrant (AZD9833) |
3 |
8535C00001 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants with Type 2 Diabetes during Ramadan (T-RAM) |
Ongoing |
Tirzepatide |
4 |
I8F-MC-GPIY |
1-Al Moosa Specialized Hospital (al ahsa) 2-Dallah Hospital (Riyadh) 3-Saudi Airlines Medical Service Center (Jeddah) 4-King Fahad Medical City (Riyadh) |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross over Study of Oral Deucrictibant Soft Capsule for On Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema |
Ongoing |
Deucrictibant |
3 |
PHA022121-C306 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) |
Ongoing |
Nipocalimab |
3 |
80202135EBF3001 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar) |
